302 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author박병배-
dc.date.accessioned2018-03-23T07:11:47Z-
dc.date.available2018-03-23T07:11:47Z-
dc.date.issued2012-12-
dc.identifier.citationCancer Research and Treatment, 2012, 44(4), P.235-241, 7P.en_US
dc.identifier.issn1598-2998-
dc.identifier.urihttps://www.e-crt.org/journal/view.php?doi=10.4143/crt.2012.44.4.235-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/51483-
dc.description.abstractPurpose Little is known about outcomes in the use of third-line chemotherapy in cases of advanced gastric cancer (AGC). The primary aim of this retrospective study was to evaluate outcomes of docetaxel-based chemotherapy in patients with AGC that progressed after both oxaliplatin-based and irinotecan-based regimens. Materials and Methods Eligible patients were those with AGC who had previous chemotherapy including fluoropyrimidine and oxaliplatin as well as fluoropyrimidine and irinotecan and who received subsequent docetaxel-based chemotherapy. Thirty-five patients were retrospectively recruited from 5 medical centers in Korea. Patients received either weekly or 3 weekly with docetaxel +/- cisplatin. Results Thirty-one out of 35 patients were evaluated for treatment response. A total of 94 cycles of chemotherapy (median, 2; range, 1 to 7) were administered. The overall response rate was 14.3%, and the disease control rate was 45.7%. The median progression-free survival (PFS) was 1.9 months (95% confidence interval [Cl], 1.1 to 2.7 months). The median overall survival (OS) was 3.6 months (95% Cl, 2.8 to 4.4 months). PFS and OS were significantly prolonged in patients of the Eastern Cooperative Oncology Group, with performance status of 0 or 1 in multivariate analysis (PFS: hazard ratio[HR], 0.411; 95% Cl, 0.195 to 0.868; p=0.020 and OS: HR, 0.390; 95% Cl, 0.184 to 0.826; p=0.014, respectively). Four of the 35 patients enrolled in the study died due to infection associated with neutropenia. Conclusion Our findings suggest that salvage docetaxel-based chemotherapy is a feasible treatment option for AGC patients with good performance status (PS), whereas chemotherapy for patients with poor PS (PS <= 2) should be undertaken with caution for those who previously failed oxaliplatin- and irinotecan-based regimens.en_US
dc.language.isoenen_US
dc.publisher대한암학회(Korean Cancer Association)en_US
dc.subjectStomach neoplasmsen_US
dc.subjectDocetaxelen_US
dc.subjectOxaliplatinen_US
dc.subjectIrinotecanen_US
dc.titleOutcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapiesen_US
dc.typeArticleen_US
dc.relation.volume44-
dc.identifier.doi10.4143/crt.2012.44.4.235-
dc.relation.page235-241-
dc.relation.journalCANCER RESEARCH AND TREATMENT-
dc.contributor.googleauthorLee, Min Jeong-
dc.contributor.googleauthorHwang, In Gyu-
dc.contributor.googleauthorJang, Joung-Soon-
dc.contributor.googleauthorChoi, Jin Hwa-
dc.contributor.googleauthorPark, Byeong-Bae-
dc.contributor.googleauthorChang, Myung Hee-
dc.contributor.googleauthorKim, Seung Tae-
dc.contributor.googleauthorPark, Se Hoon-
dc.contributor.googleauthorKang, Myoung Hee-
dc.contributor.googleauthorKang, Jung Hun-
dc.relation.code2012285702-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidbbpark-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE